FIGURE 7.

Effect of PBF509 in LID rats. (A) L-DOPA induced-motor side effects (i.e., LIDs) development upon chronic (22 days) L-DOPA (4 mg/kg) administration. AIM score was measured during a 220-min on days 1, 7, 14, and 22 after the corresponding daily L-DOPA administration. The total AIMs score over 200 min was quantified and expressed as area under the curve (AUC) ± SEM (n = 8). ^∗∗P < 0.01 and ^∗∗∗P < 0.001 one-way ANOVA with Dunnett’s post hoc test when compared to day 1. (B) Immunoreactivity of A_2AR in the striatum of dyskinetic rats. TH and A_2AR density in striatal membranes from control (R) and 6-OHDA lesioned (L) striatal hemisphere of LID animals was analyzed by immunoblot and quantified as described in Figure 4. Data are expressed as percentage of the control (R) TH or A_2AR density ± SEM of three independent experiments. Asterisks indicate data significantly different from the control condition: ^∗∗∗P < 0.001, ^∗P < 0.05 by Student’s t-test. (C) LID attenuation in chronic (22 days) L-DOPA (4 mg/kg) administered rats following administration of A_2AR antagonists. The total AIM score (area under the curve, AUC) obtained over 220 min following co-administration of L-DOPA (4 mg/kg) plus vehicle (Veh), SCH420814 (3 mg/kg) and PBF509 (3 mg/kg) are presented as mean score ± SEM (n = 6). The asterisks denote data significantly different from the vehicle condition: ^∗∗∗P < 0.001, one-way ANOVA with a Bonferroni’s post hoc test. NS: not statistically significant.